Stocktoria

REPLIGEN CORP RGEN

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1986-04-29 · LEI

REPLIGEN CORP financials (annual)

Revenue
$104.5M $141.2M $194.0M $270.2M $366.3M $670.5M $801.5M $632.4M $634.4M $738.3M 2016201720182019202020212022202320242025
Net income
$11.7M $28.4M $16.6M $21.4M $59.9M $128.3M $186.0M $35.6M -$25.5M $48.9M 2016201720182019202020212022202320242025
Free cash flow
$3.2M $12.0M $22.1M $48.7M $40.2M $51.9M $87.2M $77.7M $149.7M $93.9M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$738.3M$634.4M$632.4M$801.5M$670.5M$366.3M$270.2M$194.0M$141.2M$104.5M
R&D expense$54.2M$43.2M$42.7M$43.9M$34.3M$20.2M$19.4M$15.8M$8.7M$7.4M
SG&A expense$290.5M$263.4M$218.6M$215.8M$183.9M$119.6M$95.6M$65.7M$51.5M$30.9M
Operating income$55.2M-$35.1M$47.7M$224.7M$167.2M$69.8M$36.1M$26.0M$14.0M$16.0M
Interest expense$2.0M$1.2M$11.3M$10.8M$9.3M$6.7M$6.4M$3.8M
Income tax$13.5M-$1.5M$21.1M$33.2M$25.3M-$709,000$4.7M$4.8M-$21.1M$11,000
Net income$48.9M-$25.5M$35.6M$186.0M$128.3M$59.9M$21.4M$16.6M$28.4M$11.7M
EPS (diluted)$0.86$-0.46$0.63$3.24$2.24$1.11$0.44$0.37$0.72$0.34
Operating cash flow$117.4M$175.4M$113.9M$172.1M$119.0M$62.6M$67.2M$32.8M$17.5M$7.5M
Free cash flow$93.9M$149.7M$77.7M$87.2M$51.9M$40.2M$48.7M$22.1M$12.0M$3.2M
Cash & equivalents$566.0M$757.4M$751.3M$523.5M$603.8M$717.3M$528.4M$193.8M$173.8M$122.2M
Inventory$170.5M$143.0M$202.3M$238.3M$184.5M$95.0M$54.8M$42.3M$39.0M$24.7M
Total assets$2.9B$2.8B$2.8B$2.5B$2.4B$1.9B$1.4B$774.6M$743.5M$288.9M
Total liabilities$843.6M$856.9M$866.3M$614.0M$608.3M$373.7M$340.3M$159.1M$152.0M
Shareholders' equity$2.1B$2.0B$2.0B$1.9B$1.8B$1.5B$1.1B$615.6M$591.5M$168.8M

Growth · year-over-year · Revenue CAGR 24.3%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+16.4%+0.3%-21.1%+19.5%+83.1%+35.5%+39.3%+37.4%+35.1%+25.1%
Net income growth-171.7%-80.9%+45.0%+114.1%+179.9%+28.8%-41.4%+142.7%+25.0%
EPS growth-173.0%-80.6%+44.6%+101.8%+152.3%+18.9%-48.6%+111.8%+21.4%
Free cash flow growth-37.3%+92.7%-10.9%+68.0%+29.3%-17.5%+120.1%+84.5%+275.4%-74.3%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.